On the platform construction of R&D base, Taibo Company has established standardized Chinese medicine laboratories, chemical medicine laboratories and biopharmaceutical laboratories, including eukaryotic cell fermentation, prokaryotic cell fermentation, biological extraction, biological diagnostic reagents and pilot laboratories of new dosage forms meeting GLP standards. Equipped with 120 sets of international and domestic advanced instruments and experimental equipment, including: AKTA Explorer 100, high performance liquid chromatograph, CO2 incubator, high-speed centrifuge, etc. The company has more than 100 scholars from more than 50 famous universities, research institutes or pharmaceutical companies at home and abroad as technical consultants and technical reserves, and has several satellite laboratories at home and abroad, which provides strong intellectual support for the company's technology platform construction. In the past two years, the company has completed the declaration of more than 20 new products in five categories, obtained 3 patents with completely independent intellectual property rights, and obtained 5 grants from key scientific and technological development projects in Jilin Province and Changchun City. More than 20 projects are currently under development.
The company's business areas also involve investment, mergers and acquisitions and comprehensive management of pharmaceutical enterprises. At present, Taibo Company has invested, controlled and participated in three pharmaceutical companies: Tianjin Longbai, Ningbo Lihua and Shenzhen Langsheng. The company is gradually forming a large-scale pharmaceutical biotechnology enterprise integrating R&D, production and sales.
The soft environment of the company is excellent, and the quality management of drug production has completely entered the standardized track. A complete organizational structure and an effective operation system have been established within the enterprise, and the general manager responsibility system has been implemented. There are personnel administration department, quality control department, purchasing department, production technology department, finance department and sales department.
Taibo company has a core team with overseas entrepreneurs and innovative professional and technical personnel as the main body and many medical biotechnology research and development projects. Adhering to the reliable capital foundation of "profit growth, shareholder value growth, providing quality treatment and promotion opportunities for employees" and the mission of "ultimately benefiting human life", the company strives for perfection, constantly explores technology and product innovation, and creates a cooperation platform for the common growth of the company and employees.
Legal Representative: Tamia Liu.
Date of establishment: April 28, 2003
Registered capital: 56 million yuan.
Location: Jilin Province
Unified social credit code: 912201kloc-0/748408786w.
Business status: survival (in business, in business, in registration)
Industry: scientific research and technical services
Company type: limited liability company (wholly owned by foreign legal person)
English name: Changchun Taibo Pharmaceutical Biotechnology Co., Ltd.
Number of employees: 100-499.
Enterprise address: Guanggu Street 1050, Changchun High-tech Zone.
Scope: Research, development and transfer of biomedical technology; Production of tablets, hard capsules, granules and gels (for external use) (engaged in business within the validity period of the license); The third category of 6840 clinical laboratory analysis instruments, the third category of 6864 medical and health materials and dressings, the third category of 6846 implant materials and artificial organ production; Production and sales of cosmetics; Real estate brokerage services; Real estate information consultation; Property management (projects subject to approval according to law can only be operated after approval by relevant departments) *